Small Cell Lung Cancer Limited Stage Clinical Trial
Official title:
A Multicenter, Prospective, Randomized Study Comparing Hypofractionated Radiotherapy With Hyperfractionated Radiotherapy Combined With Concurrent Chemotherapy and Omitting Clinical Target Volumes of the Primary Tumor in Limited-stage SCLC
For most of the patients with limited-stage SCLC, thoracic radiotherapy combined with chemotherapy is the standard treatment at present. However, the optimal dose / fraction of thoracic radiotherapy for limited-stage SCLC is still in controversial.This study is designed as a prospecitive randomized non-inferiority trial.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04882033 -
Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung Cancer
|
Phase 1 | |
| Completed |
NCT03059667 -
Immunotherapy as Second-line in Patient With Small Cell Lung Cancer
|
Phase 2 | |
| Completed |
NCT01797159 -
Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer
|
N/A | |
| Completed |
NCT03214003 -
Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC
|
N/A | |
| Recruiting |
NCT04418648 -
Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy
|
Phase 2 | |
| Recruiting |
NCT05651802 -
PCI and Brain MRI Follow-up vs Brain MRI Follow-up Alone in Limited-stage SCLC Patients
|
N/A | |
| Not yet recruiting |
NCT04189094 -
Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC
|
Phase 2 | |
| Recruiting |
NCT05945745 -
Molecular Analysis and Treatment Options of SCLC
|
||
| Recruiting |
NCT04602533 -
Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)
|
Phase 2 |